We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Dr. Reddy's, a leading Indian pharmaceutical manufacturer, in partnership with OCT Clinical, an Eastern European CRO, launched a Ph3 neurology study. Despite pandemic-driven uncertainty, the enrollment target of 612 patients was reached within an impressive seven months. Through overcoming many challenges in order to figure out a cohesive strategy and solution, the teams, even within the hurdles caused by the COVID-19 nightmare, managed to undertake all activities within the project on time and complete the recruitment of 612 subjects two weeks ahead of the initially agreed schedule.
Download the case study to find out how the project team managed to complete the task.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
